Skip to main content
padlock icon - secure page this page is secure

Tumor-Inhibitory Effect of C60 Fullerene Complex with Doxorubicin

Buy Article:

$105.00 + tax (Refund Policy)

The capacity of pristine C60 fullerene with doxorubicin mixture (C60 + Dox complex) to inhibit the growth of transplanted malignant tumor in comparison with therapeutic effect of pristine C60 fullerene and Dox as separate agents, and also of pristine C60 fullerene in combination with Dox (sequential injection), is demonstrated. The tumor-inhibitory effect of the drugs investigated was tested on the Lewis lung carcinoma model using the male mice of C57Bl/6J line. It was found that C60 + Dox complex in a low therapeutic dose enhances the inhibition of tumor growth to much higher extent than that for the sequential administration of pristine C60 fullerene and Dox, or their administration as single agents, namely the maximum therapeutic effect reached 61.5% for the tumor growth inhibition. The proposed tumor treatment by C60 + Dox complex is considered to be promising in cancer therapy.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: 01 December 2015

More about this publication?
  • Nanomedicine and Nanobiology (NMB) is a multidisciplinary, peer-reviewed international journal covering the most important scientific fields of the twenty-first century- nanotechnology for medical applications. The core research areas within the scope of this journal include: nanoscale drugs and drug delivery systems; diagnosis, monitoring, prediction, therapy, prevention, and treatment of various types of cancer and other diseases; pharmaceutics, pharmacokinetic behavior, pharmacodynamics, safety and toxicology of biomedicine, molecular therapy, regenerative medicine, biomedical imaging technologies, and structural nanobiology.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Aims and Scope
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more